Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections.
Ann Pharmacother
; 38(2): 338-41, 2004 Feb.
Article
en En
| MEDLINE
| ID: mdl-14742775
ABSTRACT
OBJECTIVE:
To evaluate the role of trimethoprim/sulfamethoxazole (TMP/SMX) as an alternative to vancomycin for the treatment of severe Staphylococcus aureus infections. DATA SOURCES Clinical literature was accessed through MEDLINE (1966-February 2003) and EMBASE (1980-February 2003). Key search terms included trimethoprim/sulfamethoxazole combination and Staphylococcus aureus. DATASYNTHESIS:
An evaluation of case reports, case series, and clinical studies focusing on the use of TMP/SMX for treatment of severe S. aureus infections was conducted. The majority of the reports indicate that TMP/SMX may be effective for the treatment of infections due to low bacterial burdens of susceptible strains of S. aureus.CONCLUSIONS:
In select infections, TMP/SMX may be a useful alternative to vancomycin for treatment of severe S. aureus infections. Additional randomized studies should be conducted comparing this agent with vancomycin and linezolid.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones Estafilocócicas
/
Combinación Trimetoprim y Sulfametoxazol
/
Antiinfecciosos
Tipo de estudio:
Clinical_trials
/
Systematic_reviews
Límite:
Adult
/
Aged
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Ann Pharmacother
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2004
Tipo del documento:
Article
País de afiliación:
Estados Unidos